Connect Biopharma's COPD Drug Just Delivered Blockbuster Data — But Can a $110 Million Company Compete in a Market Dupixent Already Owns?

Shares of Connect Biopharma surged 75% to $1.74 on September 30 after the tiny San Diego biotech reported that its experimental drug slashed treatment failures by 81% in a mid-stage trial for COPD flare-ups — a result that instantly reframed the company's prospects but also raised the stakes for what comes next.

An 81% Reduction Is Hard to Ignore, Even in a Small Trial

The drug reduced treatment failure by 81% through Week 4 compared to placebo (p=0.0122) , and new moderate-to-severe exacerbations fell 85%, with hospital or emergency visits dropping 100% . The trial enrolled 159 participants globally with eosinophil counts of at least 300 cells/μL — a narrow, inflammation-driven population. The drug also significantly reduced rescue inhaler use and improved COPD symptoms, with a clinically meaningful 70 mL improvement in lung function . That lung-function result, however, was not statistically significant (p=0.16), a nuance investors should not overlook.

The COPD Biologics Market Is Real — and Already Contested

Dupixent won FDA approval for COPD in late September 2024, marking the first biologic ever authorized for the disease . The authorization positions its makers to target an estimated 300,000 U.S. adults with eosinophilic, inadequately controlled COPD . Connect's drug targets the same inflammatory pathway (IL-4 receptor alpha) as Dupixent, meaning it must prove it is better, cheaper, or different enough to carve out share against a blockbuster backed by Sanofi and Regeneron.

A $110 Million Company With $31 Million in Cash Faces an Expensive Road Ahead

Connect's market cap sits around $111 million , and cash and short-term investments stood at just $31.5 million as of June 30 . The company's net loss widened to $17.3 million last quarter alone . Running a Phase 3 COPD program — which the company plans to discuss with the FDA — would likely cost multiples of its current treasury, meaning dilutive fundraising or a partnership is virtually certain.

Analysts See Upside, But the Stock Still Trades at a Fraction of Targets

Wall Street consensus remains Buy, with an average price target of $6.52 — nearly 4x today's price. Oppenheimer recently cut its target from $8 to $5 but kept an Outperform rating . The gap between analyst optimism and the sub-$2 share price reflects the market pricing in severe execution and financing risk. Today's data narrows that gap, but does not close it.